Synonyms: LFA-2, SRBC
Siplizumab (Anti-CD2) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. MW:145.5 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Siplizumab (Anti-CD2) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. MW:145.5 KD.
|
|---|
| CAS No. | 288392-69-8 |
|---|---|
| Molecular Weight | 145.5 kDa |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT06972069 | RECRUITING | Drug: Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), | Kidney Failure; Transplant Recipient (Kidney); Transplant Tolerance; Immunosuppresion; Immunosuppression After Kidney Transplantation | Tatsuo Kawai, MD, PhD | 2025-05-31 | EARLY_PHASE1 |
| NCT05900401 | ACTIVE_NOT_RECRUITING | Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab|Dru | Kidney Failure; Kidney Transplant; Complications; Chimera | Massachusetts General Hospital | 2023-10-01 | PHASE1; PHASE2 |
| NCT07508787 | RECRUITING | Drug: Siplizumab|Drug: Rabbit anti-thymocyte globulin | Renal Transplant Failure and Rejection | Nefro Avillion Clinical Development, LLC | 2026-06-29 | PHASE2 |
| NCT06455280 | RECRUITING | Drug: Siplizumab | Autoimmune Liver Disease; Liver Transplant Disorder; Autoimmune Hepatitis; Primary Sclerosing Cholangitis; End Stage Liver DIsease; Cirrhosis, Liver | Elizabeth C. Verna | 2024-09-11 | PHASE1 |
| NCT06326476 | RECRUITING | Drug: Siplizumab | Hidradenitis Suppurativa | University of Alabama at Birmingham | 2025-05-09 | EARLY_PHASE1 |
| NCT04540380 | ACTIVE_NOT_RECRUITING | Drug: Rituximab, Fludarabine, Cyclophosphamide, Thymic irrad | Renal Failure | Massachusetts General Hospital | 2021-09-01 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-07-22)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.